Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.71 USD | -6.62% | -4.95% | +113.05% |
Jun. 02 | Transcript : Cullinan Therapeutics, Inc. - Special Call | |
Jun. 01 | Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib | CI |
Chart calendar Cullinan Therapeutics, Inc.
Upcoming events on Cullinan Therapeutics, Inc.
Past events on Cullinan Therapeutics, Inc.
2024-06-01 10:00 am | American Society of Clinical Oncology Meeting - Poster Number: 2588 |
2024-05-29 11:30 am | TD Cowen Oncology Innovation Summit |
2024-05-15 04:05 pm | Q1 2024 Earnings Release |
2024-04-16 08:00 am | Business Update Call |
2024-03-14 07:00 am | Q4 2023 Earnings Release |
2024-03-13 08:00 am | Leerink Partners Global Biopharma Conference - Fireside Chat |
2024-03-05 10:30 am | TD Cowen Health Care Conference - Panel |
2024-01-11 01:30 pm | JPMorgan Healthcare Conference |
2023-11-30 08:20 am | Evercore ISI HealthCONx Conference |
2023-11-14 03:35 pm | Stifel Healthcare Conference |
2023-11-08 07:00 am | Q3 2023 Earnings Release |
2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Poster Number: 1024 |
2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Poster Number: 194 |
2023-11-03 01:30 pm | TD Cowen Fall Oncology Innovation Summit |
2023-11-03 12:00 pm | Society for Immunotherapy of Cancer Meeting - Poster Number: 771 |
2023-11-03 12:00 pm | Society for Immunotherapy of Cancer Meeting - Poster Number: 1093 |
2023-11-03 12:00 pm | Society for Immunotherapy of Cancer Meeting - Poster Number: 1171 |
2023-09-28 09:45 am | Cantor Global Healthcare Conference |
2023-09-13 10:50 am | Morgan Stanley Global Healthcare Conference |
2023-09-11 07:00 am | H.C. Wainwright Global Investment Conference |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 6,00 - | 18,9 18,9 0.08% | 0,00 138 - | 0,00 0,00 - | 1,88 |
EBITDA Million USD | Released Forecast Spread | 0,00 | -60,3 -43,9 -37.16% | -67,9 -58,0 -17.09% | 145 145 -0.24% | -190 -192 0.78% | -169 |
EBIT Million USD | Released Forecast Spread | -22,3 | -60,3 -44,0 -37.07% | -68,0 -55,6 -22.2% | 145 145 -0.32% | -191 -192 0.81% | -184 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -59,5 -46,9 -26.78% | 0,00 0,00 - | 151 148 2.16% | -169 -170 0.72% | -161 |
Net income Million USD | Released Forecast Spread | 0,00 | -51,8 -34,9 -48.41% | -65,6 -52,9 -23.93% | 111 107 3.95% | -153 -170 10.08% | -165 |
EPS USD | Released Forecast Spread | -1 127 | -3,64 -2,99 -21.84% | -1,52 -1,26 -20.32% | 2,38 2,33 2.15% | -3,69 -4,08 9.47% | -3,01 |
Announcement Date | 02/11/20 | 30/03/21 | 17/03/22 | 09/03/23 | 14/03/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 275 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
EBIT Million USD | Released Forecast Spread | -32,7 -24,9 -31.09% | 240 241 -0.73% | -29,8 -36,1 17.59% | -32,6 -32,1 -1.57% | -62,8 -59,2 -5.94% | -37,6 -36,9 -2.04% | -45,2 -41,7 -8.54% | -45,5 -47,1 3.52% | -43,0 -47,0 8.59% | -45,1 | -47,7 | -50,0 | -59,0 | -62,0 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 240 242 -0.62% | -27,4 -35,0 21.69% | -28,9 -30,8 6.09% | -58,1 -56,2 -3.47% | -32,2 -35,5 9.13% | -39,2 -39,8 1.62% | -39,7 -41,6 4.62% | -37,3 -43,4 13.88% | -40,3 | -42,5 | -44,0 | -59,0 | -61,5 | |
Net income Million USD | Released Forecast Spread | -12,1 -24,6 50.9% | 175 243 -28% | -24,8 -51,5 51.79% | -26,8 -32,1 16.52% | -58,0 -42,1 -37.69% | -32,2 -41,8 22.86% | -39,2 -39,5 0.79% | -23,8 -41,6 42.79% | -37,1 -42,9 13.37% | -40,6 | -43,6 | -46,2 | -59,0 | -62,0 |
EPS USD | Released Forecast Spread | -0,27 -0,55 50.91% | 3,77 5,42 -30.4% | -0,54 -0,97 44.14% | -0,59 -0,67 11.28% | -1,42 -0,98 -44.9% | -0,82 -0,97 15.46% | -0,91 -0,94 2.99% | -0,54 -0,96 43.6% | -0,86 -0,92 6.52% | -0,72 | -0,73 | -0,74 | -0,86 | -0,89 |
Announcement Date | 16/05/22 | 10/08/22 | 14/11/22 | 09/03/23 | 11/05/23 | 10/08/23 | 08/11/23 | 14/03/24 | 15/05/24 | - | - | - | - | - |
2024-07-15 01:45 am | ADDLIFE AB: Q2 2024 Earnings Release |
2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
2024-07-23 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | ICON PUBLIC LIMITED COMPANY: Q2 2024 Earnings Release (Projected) |
2024-07-24 | LONZA GROUP AG: Q2 2024 Earnings Release |
2024-07-25 01:00 am | BACHEM HOLDING AG: Q2 2024 Earnings Release |
2024-07-25 | PHARVARIS N.V.: Q2 2024 Earnings Release (Projected) |
2024-07-26 01:00 am | BB BIOTECH AG: Q2 2024 Earnings Release |
Past sector events for Cullinan Therapeutics, Inc.
2024-05-29 04:01 pm | IMMUNOVANT, INC.: Q4 2024 Earnings Release |
2024-05-23 07:00 am | CUREVAC N.V.: Q1 2024 Earnings Release |
2024-05-22 01:00 am | EVOTEC SE: Q1 2024 Earnings Release |
2024-05-21 05:14 pm | ALVOTECH: Q1 2024 Earnings Release |
2024-05-21 07:00 am | EXSCIENTIA PLC: Q1 2024 Earnings Release |
2024-05-17 02:00 am | BIOARCTIC AB: Q1 2024 Earnings Release |
2024-05-15 04:05 pm | CULLINAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | PERSPECTIVE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | KYVERNA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CGEM Stock
- Calendar Cullinan Therapeutics, Inc.